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A murine model of genital infection with a thymidine kinase-deficient (tk) strain of herpes simplex virus type 2 (HSV-2) 
was utilized to examine the local urogenital antibody response to HSV-2. Vaginal inoculation with HSV-2 tk- protected 
against a subsequent genital challenge with a lethal dose of virulent HSV-2. After primary vaginal infection, predominantly 
HSV-specific IgG antibodies were detected in serum and vaginal secretions. HSy-specific IgG antibody-secreting cells (ASC) 
were detected first and in greatest numbers in the genital lymph nodes (gLN) after primary HSV-2 tk- inoculation. HSV- 
specific IgG or IgA ASC were not detected in the urogenital mucosa after primary HSV-2 vaginal infection. Vaginal HSV-2 
challenge of HSV-immune mice resulted in increased HSV-specific serum IgG antibody and vaginal IgA antibody titers. HSV- 
specific IgG ASC were detected by 4 days postchallenge in gLN and by Days 6 and 7 postchallenge in the spleen and 
genital mucosa. These results suggest that urogenital humoral responses originate in the gLN following HSV genital infection 
and that gLN may serve as the primary source of the HSV-specific IgG- and IgA-secreting cells present in the urogenital 
mucosa after vaginal challenge. ¢ 1995 Academic Press, Inc. 
INTRODUCTION 
The initial encounter of the host with many pathogens, 
including those causing sexually transmitted diseases, 
occurs at a mucosal surface. Although progress has 
been made in understanding the immune responses that 
provide protection at the mucosal surfaces of the airways 
and digestive tract, immune responses in the mucosa of 
the urogenital tract are less understood. 
Herpes simplex type 2 (HSV-2) infects both the oral 
and genital mucosa of humans and is a significant cause 
of morbidity in the United States. The ability of HSV-2 to 
rapidly develop latent infections in neural ganglia follow- 
ing infection of the genital mucosa suggests that the 
best way to prevent HSV-2 disease would be to develop 
immunization strategies capable of eliciting local im- 
mune responses which would prevent or limit primary 
and latent HSV infections. To this end, it is important o 
identify the components of a protective immune response 
within the urogenital mucosa so that new vaccines, adju- 
vants, or methods of delivery can be developed to effec- 
tively elicit the appropriate type of immune response at 
the viral site of entry. 
The urogenital tract is generally considered part of 
the common mucosal immune system (McDermott and 
Bienenstock, 1979; Mestecky, 1987). The best studied 
regions responsible for induction of mucosal immune 
responses are the discrete lymphoid follicles in the intes- 
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tine and respiratory tract (Bienenstock, 1984; Marshall et 
aL, 1989). Antigens taken up by specialized epithelial 
cells at these mucosal inductive sites are delivered to 
underlying lymphoid tissue where they are processed 
and presented to immunocompetent T and B lymph@ 
cytes. After maturation, these cells migrate to the lamina 
propria regions of both local and distant mucosal sites. 
Thus, immunization of mucosal immune inductive sites 
can result in the induction of humoral responses in which 
antibodies can be detected locally and in regionally dis- 
tinct mucosal sites (Weisz-Carrington et aL, 1979; Wu 
and Russell, 1993), although the levels of antibody are 
greatest at the site of antigen application (Ogra and Kar- 
zon, 1969; Pierce and Cray, 1982). In this regard, it would 
seem most efficient to directly immunize the urogenital 
mucosa in order to provide optimal protection against 
sexually transmitted pathogens. 
Previous studies have shown that antigen-specific IgG 
and IgA antibodies can be detected in vaginal secretions 
as a result of direct immunization of the genital tract with 
soluble protein (Parr et aL, 1988; Thapar et aL, 1990a) or 
viral antigens (Lehner et aL, 1992b). Although viral infec- 
tion of the gut or respiratory mucosa usually results in 
production and secretion of relatively large quantities of 
antigen-specific IgA, intravaginal infection of mice with 
an attenuated HSV-2 virus (McDermott et aL, 1984) or 
simian immunodeficiency virus (Miller et aL, 1992) has 
been reported to result in predominantly antigen-specific 
vaginal IgG and little, if any, vaginal IgA antibody. In this 
regard immune responses resulting from direct immuni- 
zation of the genital mucosa are apparently different than 
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those arising at other mucosal sites. In mice this is prob- 
ably the result of an apparent lack of organized immune 
inductive lymphoid tissue in the female reproductive tract 
(Thapar et al., 1990b). 
Antibodies present in vaginal secretions are most 
likely important in protection of the urogenital mucosa. 
Vaginal antibodies may result from local production from 
plasma cells within the urogenital mucosa or as a result 
oftransudation from the serum (Chipperfield and Evans, 
1975; Sullivan and Wira, 1983). Therefore, it has been 
difficult o obtain unambiguous information concerning 
the induction of the urogenital antibody response. In this 
study, we extend previous reports on the urogenital hu- 
moral response elicited by genital infection with HSV-2 
to include an examination of the induction and kinetics 
of HSV-specific antibody secreting cell responses within 
the urogenital mucosa after infection with a viral 
pathogen. 
MATERIALS AND METHODS 
Mice 
Four to 8-week-old female BALB/c mice were obtained 
from Harlan Sprague Dawley, inc. (Indianapolis, IN). 
Virus 
The bromodeoxyuridine-resistant mutant HSV-2 333 
tk- (Stanberry et al., 1985), wild type HSV-2 strain 333, 
and HSV-2 strain 186 were obtained from Dr. Lawrence 
Stanberry (Children's Hospital Medical Center, Cincin- 
nati, OH). Virus stocks were grown in Vero cell mono- 
layers and prepared by two cycles of freeze/thaw and 
removal of cellular debris by centrifugation. Viral stocks 
were stored at -70 ° and samples were titrated on Vero 
cell monolayers. 
Genital herpes infection 
Anesthetized BALB/c mice were infected with HSV-2 
strain 333 tk- (Stanberry et aL, 1985) after preswab with 
a cotton pledget by insertion of a type 1 calgiswab 
soaked with 106 PFU HSV-2 strain 333 tk-into the vagina 
forthe duration of anesthesia. Infection and viral replica- 
tion were detected by daily vaginal swabbing with a 
moist type 1 calgiswab. The swab was added to 1 ml 
media and subsequently titered on VERO cell mono- 
layers. HSV-immune and age-matched naive mice were 
challenged by genital inoculation with 106 PFU fully viru- 
lent HSV-2 strain 333 or strain 186 using the same 
method. 
HSV-2 antigen preparation 
HSV-2 glycoprotein was prepared similarly to that de- 
scribed previously (Stanberry eta/., 1987). HSV-2-infected 
HFP-2 monolayers were detergent solubilized and glyco- 
proteins purified by passage over lentil-lectin Sepharose 
columns. Control cell extract (mock antigen) was pre- 
pared from uninfected HEP-2 monolayers by detergent 
solubilization and clarification. Stock solutions were 
stored at -70 °. 
ELISA for HSV-specific antibodies 
Sera were obtained by collecting blood from the orbital 
plexus. Vaginal secretions were sampled from an individ- 
ual animal by four repetitions of introducing 50 #1 PBS 
into the vaginal lumen, trituration of the sample, and pool- 
ing of the four washes. 
ELISA assays were performed similarly to those de- 
scribed by Bernstein et al. (1987). Briefly, wells of a 96- 
well EIA plate (COSTAR, Cambridge, MA) were coated 
with. HSV-2 glycoprotein or mock antigen at 1 #g/ml and 
blocked with BSA/PBS. Serial dilutions of serum or vagi- 
nal wash were added in duplicate and detection of IgG or 
IgA antibbdies was performed by addition of biotinylated 
goat anti-mouse IgG or anti-mouse IgA (Caltag Labora- 
tories, Inc., San Francisco, CA) followed by peroxidase- 
conjugated goat anti-biotin (Vector Laboratories, Inc., 
Burlingame, CA) and developing with o-phenylenedi- 
amine dihydrochloride (Sigma, St. Louis, MO). The end- 
point titer was considered to be the reciprocal of the last 
sample dilution in which the mean OD49o value for a HSV- 
2 glycoprotein well was greater than 0.1 OD49o units that 
of the sample on a mock antigen well. 
Lymphocyte populations 
Single cell suspensions of spleens and the iliac and 
para aortic lymph nodes draining the genital organs 
(gLN) were prepared by passage through stainless steel 
mesh. Peripheral blood was collected via capillary tube 
at the orbital plexus and aspirated into Alsever's solution, 
and peripheral blood lymphocytes (PBL) were obtained 
by Ficoll separation. To obtain urogenital lymphocytes, 
genital tracts (vagina, cervix, and uterine horns) were 
removed from groups of six-eight mice, minced, and 
digested with the neutral protease, Dispase (Boehringer 
Mannheim Corp., Indianapolis, IN) at 1.5 mg/ml in EDTA- 
free Puck's solution. Three successive digests were per- 
formed for 30 min at 37 °. Digests were pooled, and lym- 
phocytes enriched by passing the cell fraction over Per- 
coil gradients. The lymphocyte-rich population present 
atthe 55/70% interface was collected and cultured at 37 ° 
for 2 hr to further remove adherent epithelial and fibro- 
blast cells. 
ELISPOT assay 
Ninety-six-well filtration plates backed with a nitrocel- 
lulose membrane (Millipore Corp., Bedford, MA) were 
coated with 100 #l/well HSV-2 glycoprotein, mock anti- 
gen, or affinity-purified goat anti-mouse immunoglobulin 
at 10 #l/ml in carbonate buffer, pH 8.8. After overnight 
incubation at 4 °, the wells were blocked with sterile 7.5% 
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FIG, 1. Clearance of HSV-2 from genital tracts. (A) Primary vaginal inoculation. Five-week-old BALB/c mice were inoculated vaginally with 106 
pFIj HSV-2 333 tk-. Daily vaginal swabs were taken and titered on Vero cell monolayers. Results are expressed as the mean titer + SEM for 13 
mice. (B) HSV-2 vaginal challenge, Eight-week-old naive mice (©) or mice infected 3 weeks previously with HSV-2 333 tk- (lB) were challenged 
intravaginaliy with 106 PFU HSV-2 186. Results are from a representative xperiment with five HSV-2 immune and six naive mice, 
BSA in PBS. Single cell suspensions of spleen, genital 
lymph node, urogenital tract digests, or PBL in RPMI plus 
10% FCS were plated and incubated at 37 ° for 15 hr. The 
number of plasma cells in each preparation secreting 
HSV-2 glycoprotein-specific IgG, IgA, or IgM antibody 
was determined by washing the plate with PBS to remove 
cells and developing the plate by the addition of biotinyl- 
ated goat anti-mouse IgG, anti-lgA, or anti-lgM (Caltag 
Laboratories), followed by avidin-peroxidase. Spots rep- 
resenting individual antibody secreting cells were visual- 
ized by developing with peroxidase substrate containing 
H202 and 3-amino-9 ethylcarbazole in acetate buffer. Re- 
sults are expressed as the mean number of antibody- 
secreting cells (ASC) per million mononuclear cells in a 
given cell preparation. 
RESULTS 
Development of protective immunity by genital 
inoculation with attenuated HSW2 
Due to the neurovirulence of wild type HSV-2 in mice 
(Nahmias et aL, 1967; Overall et aL, 1975), a thymidine 
kinase-deficient mutant of HSV-2 was used to induce 
protective urogenital immune responses. The ability of 
BALB/c mice to clear the tk HSV-2 mutant from the 
urogenital tract was assessed by taking vaginal swabs 
on various days after intravaginal infection with 106 PFU. 
As shown in Fig. 1A, titers peaked on Day 2 postinfection, 
declined daily thereafter, and were essentially undetect- 
able by Day 7 postinfection. Infectious virus was detected 
only in vaginal secretions and vaginal epithelia following 
intravaginal inoculation of HSV-2 tk . In agreement with 
the results of Overall eta/. (1975) virus was never isolated 
from blood, spleen, liver, or kidney homogenates up to 
9 days after intravaginal inoculation (data not shown). 
Perivaginal lesions occasionally developed and usually 
healed within 1 to 2 weeks. 
BALB/c mice infected vaginally with HSV-2 333 tk 
developed protective immune responses. Three weeks 
following vaginal infection with various doses of HSV-2 
333 tk-, mice were challenged vaginally along with age- 
matched naive controls with a lethal dose of wild type 
HSV-2. Protection from death was dose dependent with 
maximal protection (100%) afforded by previous infection 
with 106 PFU HSV-2 strain 333 tk- (data not shown). In 
contrast to nonimmune mice, HSV-2 immune mice 
cleared virus from the vagina by Day 6 after vaginal re- 
challenge with virulent HSV-2 (Fig. 1B). 
HaY-specific antibody response after primary vaginal 
HSV-2 tk- inoculation 
The kinetics of the systemic and local HSV-specific 
antibody response following primary vaginal infection 
with HSV-2 333 tk- is shown in Fig. 2. HSV-specific lgG 
antibodies were detected in vaginal washes (Figure 2A) 
or serum (Figure 2B) by Day 10 postinfection, lgG anti- 
body titers continued to rise through Day 24. HSV-spe- 
cific IgA antibodies were not detected until Day 18 postin- 
oculation in both serum and vaginal secretions and lev- 
els increased through Day 24. 
An ELISPOT assay was utilized to characterize the 
local HSV-specific humoral response at the cellular level. 
Initially, the kinetics of the HSV-specific ASC response 
in the draining gLN (lilac, para-aortic lymph nodes) was 
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FiG. 2. Kinetics of the HSV-specific antibody response in vaginal secretions and serum following primary vaginal inoculation with HSV-2 333 tk-. 
Vaginal washes (A) and serum (B) were obtained from mice on the days indicated after primary vaginal inoculation with HSV-2 333 tk- and titers 
determined by ELISA. IgA (O) and IgG ([]) titers for seven mice from a representative xperiment of four performed are expressed as the geometric 
mean (Ioga for vaginal washes and Iog~0 for serum) + SEM. A titer of 1 (log3) for vaginal washes and 1.67 (Iog~o) for serum represents the limits of 
detection for this experiment. Samples with a titer below the level of detection were arbitrarily assigned a value of 0.5. Titers of HSV-specific IgG 
and IgA antibody from serum and vaginal washes of uninoculated mice always fell below the limits of detection and are omitted from the figure 
for clarity. 
determined in order to provide a time frame to best detect 
HSV-specific ASO in various tissues• Lymphocytes from 
gLN of mice inoculated intravaginally with HSV-2 333 tk- 
were obtained between Days 5 and 16 postinfection and 
the number of HSV-2 glycoprotein-specific IgG-, IgA-, and 
PgM-secreting lymphocytes was determined. The results 
of a representative xperiment of three performed are 
shown in Fig. 3. HSV-specific IgM ASC were present in 
120 
100 
80 
60 
40 
20 
0 
5 7 9 12 16 
DAY POST INTRAVAGINAL INOCULATION 
FIG. 3. Kinetics of HSV-specific antibody secreting ceil response in 
the genital ymph nodes following primary vaginal infection with HSV- 
2333 tk-. Mice were inoculated intravaginally with 10 e PFU HSV-2 333 
tk-. Pooled single cell suspensions of draining genital lymph nodes 
from two mice/time point were prepared on the indicated day and 
plated on HSV-2 glycoprotein or mock antigen-coated nitrocellulose 
membranes. Plates were then developed to detect IgM- (A), IgA- (O), 
or IgG-(rq) antibody-secreting cells as described under Materials and 
Methods. Results from a representative xperiment of three performed 
are shown and expressed as the mean _ SD of triplicate wells. 
the draining genital lymph nodes by Day 5 postinfection, 
peaked between Days 5 and 7, and declined slowly 
thereafter. HSV-specific igG ASC were present in the gLN 
at Day 7 and peaked between Days 7 and 9 postinfection. 
Although the number of IgG ASC declined thereafter, 
significant numbers were present as late as Day 16 in 
the gLN. Low numbers of HSV-specific IgA ASC were 
detected between Days 7 and 9 postinfection. 
To examine if vaginal HSV-specific antibody was pro- 
duced locally in the urogenital mucosa by HSV-specific 
ASC, lymphocytes were isolated from genital tracts (va- 
gina, cervix, and uterine horns) at various times after 
intravaginal infection with HSV-2 tk-and the number of 
HSV-specific ASC was determined by ELISPOT analysis. 
As shown in Table 1, HSV-specific ASC were essentially 
undetectable within the urogenital mucosa and spleen 
on Days 8, 15, or 35 postinfection. By contrast, HSV- 
specific ASC were detected in the genital lymph nodes 
of these animals on all assay days. The isotype profile 
of the primary humoral response after HSV-2 tk- infection 
as determined by ELISPOT assay (Table 1) corroborated 
the results obtained by ELISA (Fig. 2). 
HSV-specific antibody response following vaginal 
challenge with virulent HSV-2 
BALB/c mice previously inoculated vaginally with HSV- 
2 tk- were challenged vaginally with a lethal dose of 
virulent HSV-2. In contrast to unimmunized mice, all mice 
survived the infection and cleared the virus from the va- 
gina (data not shown). The titers of HSV-specific IgG and 
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TABLE 1 
HSV-SPECIFIC ANTIBODY-SECRETING CELLS FOLLOWING 
PRIMARY VAGINAL INFECTION 
HSV-specific ASC/ 
million mononuclear 
cells (SEM)" 
IgG IgA 
Day 8 
HSV-2, genital digest b O (0) 1 (1) 
HSV-2= PaL 0 (0) 0 (0) 
HSV-2: gLN 151 (50) 6 (4) 
HSV-2, spleen O (0) 0 (0) 
Naive= spleen 0 (0) 0 (0) 
Day 15 
HSV-2, genital digest 0 (0) 0 (0) 
HSV-2: PBL 2 (0) 3 (1) 
HSV-2, gLN 310 (64) 3 (2) 
HSV-2: spleen 2 (2) 1 (1) 
Naive, spleen 0 (0) 2 (2) 
Day 35 
HSV-2: genital digest 1 (1) O (0) 
HSV-2: PBL 1 (1) 1 (1) 
HSV-2: gLN 8 (2) 2 (1) 
HSV-2: spleen 2 (1) 2 (2) 
Naive, spleen 0 (0) 0 (0) 
The results of one experiment for Day 15, three experiments for 
Day 8 and two experiments for Day 35 are shown. No IgG and IgA ASC 
were detected in naive genital lymph nodes or naive genital digests. 
b Lymphocytes from the indicated tissues from groups of six-eight 
HSV-2 tk -inoculated (HSV-2) or naive mice were pooled and assayed 
for the presence of HSV-2 glycoprotein-specific antibody secreting cells 
as described under Materials and Methods. 
IgA present in vaginal secretions and serum fol lowing 
primary and chal lenge inoculation are shown in Table 2. 
Although the quantity of HSV-specific IgG antibody pres- 
ent in vaginal secretions general ly increased after chal- 
lenge HSV-2 genital infection, a greater increase was 
apparent in the amount of HSV-specific IgA secreted into 
the vaginal lumen. The HSV-specific mean IgG and IgA 
titers were thus nearly equivalent fol lowing HSV-2 vagi- 
nal challenge. In contrast, HSV-specific IgG antibodies 
remained the predominant isotype in the serum after 
vaginal chal lenge inoculation. Thus, the isotype profile 
of HSV-specific antibody in vaginal secretions after a 
HSV-2 chal lenge infection did not reflect that of serum 
antibody. 
HSV-specific ant ibody-secret ing cells in the urogenital  
mucosa fo l lowing HSV-2 vaginal chal lenge 
HSV-specific ASC were present in gLN of HSV-2 tk 
immune mice after genital chal lenge with virulent HSV- 
2 as early as Day 4 postinfection. Low numbers of HSV- 
specific IgA ASC could be detected in gLN on all days 
postinfection (Table 3); however, HSV-specific IgG ASC 
clearly dominated the ASC response. Very low numbers 
TABLE 2 
HSV-SPECIFIC IgG AND IgA ANTIBODY IN SERUM AND VAGINAL SECRETIONS 
AFTER PRIMARY AND CHALLENGE HSV-2 GENITAL INFECTION 
Primary vaginal Challenge vaginal 
infection infection 
Geometric mean [log 3] + (SEM) a 
Vaginal washes 
IgG 3.3 (0.47) 3.95 (0.64) 
IgA 1.7 (0.39) 3.56 (0.50) 
Geometric mean [log10] _+ (SEM) 
Serum 
IgG 4.48 (0.12) 5.65 (0.15) 
IgA 1.43 (0.30) 2.24 (0.64) 
Results are expressed as the geometric mean + SEM from two 
experiments. Vaginal washes were taken Days 18 (IgG) and 20 (IgA) 
after primary vaginal infection and Days 13 (IgA) and 15 (IgG) after 
challenge HSV-2 vaginal infection. Sera was obtained Day 22 after 
primary vaginal infection and Day 15 after challenge vaginal HSV-2 
infection. HSV-specific antibody titers of uninoculated mice fell below 
the limits of detection and are omitted for clarity. 
of antigen-specif ic IgG ASC were detected in the spleen 
by Day 4 postchal lenge with increased numbers on Days 
6 and 7 after HSV-2 vaginal challenge. 
HSV-specific IgG ASC were present at levels slightly 
above background as early as Day 4 postchallenge in 
the genital tracts of HSV-2-challenged mice (Table 3). 
Greater numbers of HSV-specific IgG- and IgA-secreting 
cells were detected by Days 6 and 7 postchallenge. 
TABLE 3 
PRESENCE OF HSV-2 GLYCOPROTEIN-SPECIFIC ANTIBODY-SECRETING 
CELES IN THE GENITAL MUCOSA FOLLOWING HSV-2 VAGINAL CHALLENGE 
INFECTION 
Mean HSV-specific 
ASC/million 
mononuclear cells 
(SEM) ~ 
IgG IgA 
Day 4 postinoculation 
HSV-2= PaL 4 (3) 0 (0) 
HSV-2: genital mucosa 3 (2) 0 (0) 
HSV-2= genital lymph nodes 164 (94) 5 (5) 
HSV-2: spleen 7 (1) 0 (0) 
Naive, spleen 0 (0) 0 (0) 
Days 6-7 postinoculation 
HSV-2, PBL 1 (1) 0 (0) 
HSV-2, genital mucosa 18 (3) 12 (6) 
HSV-2: genital lymph nodes 152 (68) 13 (6) 
HSV-2= spleen. 50 (31) 2 (0) 
Naive= spleen 0 (0) 0 (0) 
a Results are expressed as the mean + SEM from two experiments 
for Day 4 and from four experiments for Days 6 and 7. 
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These ASC appear to represent genital mucosal lympho- 
cytes and not PBL from contaminating peripheral blood 
based on the lack of detectable HSV-specific ASC in 
equivalent numbers of peripheral blood lymphocytes 
from the HSV-immune genital tract donors. The antigen- 
specific IgA ASC response detected in populations of 
lymphocytes isolated from the urogenital mucosa was 
approximately equivalent to the HSV-specific IgG ASC 
response. Importantly, in these experiments, the HSV- 
specific IgG ASC,IgA ASC ratio for urogenital mucosa 
lymphocytes did not mirror that of genital lymph node 
lymphocytes. 
DISCUSSION 
Immunization of the female urogenital tract with solu- 
ble protein (Parr et al., 1988; Thapar et al., 1990a) or 
recombinant, particulate viral antigens (Lehner et aL, 
1992b) results in a local humoral response characterized 
by antigen-specific IgG and IgA antibody in vaginal se- 
cretions. In the present study, the development of the 
local urogenital antibody response following intravaginal 
inoculation with live virus was examined. The resulting 
humoral response represented one component of a pro- 
tective immune response to a sexually transmitted patho- 
gen. In agreement with other studies examining urogeni- 
tal antibody responses to live microorganisms (McDer- 
m0tt et al., 1990; Miller et aL, 1992), IgG antibody 
represented the predominant isotype in both serum and 
vaginal secretions after primary vaginal virus inoculation. 
However, in contrast to the results obtained by McDer- 
m0tt eta/. (1990), low levels of serum and vaginal HSV- 
specific IgA antibody were detected 18 days after primary 
intravaginal inoculation with HSV-2 tk-, These results 
add to a growing body of evidence suggesting that al- 
though local antibody responses can be induced by im- 
munization of the vaginal mucosa, the urogenital tract 
does not appear to be a good inductive site for secretory 
IgA responses (Yang and Schumacher, 1979; Lehner et 
aL, 1992a; Haneberg et aL, 1994). 
0D4 + and CD8 + T lymphocytes, Langerhans cells, and 
macrophages are present in the epithelia of the vagina 
and cervix (Parr and Parr, 1991; Parr et aL, 1991). IgG + 
and IgA + B cells have been detected in the fallopian 
tubes, cervix, and vagina of humans (Kutteh et aL, 1988) 
and mice (Parr and Parr, 1985). However, immunohisto- 
chemical analyses have demonstrated a lack of orga- 
nized lymphoid tissue in the reproductive tracts of female 
mice (Thapar et al., 1990b), suggesting that urogenital 
immune responses may originate in the draining genital 
lymph nodes. In the present study, HSV-specific ASC 
were detected in the gLN, but not the genital mucosa, 
as early as Day 5 after primary vaginal inoculation with 
HSV-2 tk-. Although it is possible that HSV-specific B 
0ells were present in the urogenital mucosa in numbers 
belowthe level of detection by ELISPOT assay, the detec- 
tion of large numbers of HSV-specific B cells in the gLN 
on the days that antibody is first detected in the serum 
and vaginal secretions is consistent with a gLN origin 
for the urogenital humoral response. The results of the 
present study are most consistent with a model in which 
Langerhans cells and macrophages present in the geni- 
tal epithelia take up antigen and migrate to the draining 
lymph nodes where a local immune response is initiated 
(Miller, 1994). 
The source of antigen-specific vaginal antibody follow- 
ing HSV-2 tk- inoculation appears complex. McDermott 
et al. (1990) detected HSV-specific IgG antibody in vagi- 
nal secretions following intravaginal, but not intraperito- 
neal, infection with HSV-2 tk-. Further, systemically ad- 
ministered HSV-specific IgG monoclonal antibodies were 
not detected in vaginal secretions. Taken together, these 
results suggested a local (mucosal) rather than serum 
origin for v.aginal HSV-specific antibodies. In the present 
study, HSV-specific ASC were apparently absent in the 
urogenital mucosa after primary genital infection, sug- 
gesting that local plasma cells contributed little, if any, 
to vaginal antibody titers. Vaginal fluid is complex and 
may contain components derived from cervical, uterine, 
or peritoneal secretions as well as transudated plasma 
proteins (Mardh, 1993). Further, transudation of serum 
immunoglobulin into genital tissues and secretions is 
influenced by inflammation (Chipperfield and Evans, 
1975), glucocorticoids (Wira et al., 1990), and hormones 
(Sullivan and Wira 1983, 1984). Polymeric serum IgA has 
been shown to be transported into saliva, tears, nasal 
secretions, and bile by secretory component-mediated 
transfer (South et al., 1966; Russell et al., 1982; Renegar 
and Small, 1991; Sullivan and Allansmith, 1984). It seems 
possible that dimeric serum IgA which enters genital 
tissue may be transported into vaginal secretions in a 
similar fashion, thus adding to the local concentration of 
antibody. In the present study, the isotype profile of HSV- 
specific antibodies in vaginal secretions following pri- 
mary vaginal HSV-2 tk- infection generally mirrored that 
of antigen-specific antibodies in the serum. HSV-specific 
IgG antibodies produced as a result of a primary vaginal 
HSV-2 infection were detected in the serum of some mice 
before they could be detected in vaginal secretions. By 
contrast, in four kinetics experiments performed, HSV- 
specific IgG was never detected first in vaginal secre ~ 
tions (data not shown). These results, together with an 
apparent lack of HSV-specific urogenital ASC, suggest 
that HSV-specific vaginal antibody following primary in- 
travaginal inoculation is serum-derived. 
The antibody response following HSV-2 vaginal chal- 
lenge, however, was composed in part of locally pro- 
duced antibody. Urogenital HSV-specific IgG- and IgA- 
secreting cells were readily detectable by Days 6 and 
7 after HSV-2 vaginal challenge. Although these cells 
may represent resident urogenital cells primed by the 
initial HSV-2 tk- inoculation, given the magnitude of the 
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local lymph node response it seems more likely that 
they represent antigen-specific gLN B cells which mi- 
grated to the urogenital mucosa following initial inocula- 
tion or after HSV-2 vaginal challenge. A higher propor- 
tion of HSV-specific IgA ASC was found in the urogenital 
mucosa than in the gLN following HSV vaginal chal- 
lenge, suggesting that some of the HSV-specific ASC 
in the mucosa may have originated in a site other than 
the gLN or that IgA committed HSV-specific B ceils pref- 
erentially homed to the urogenital mucosa. The pres- 
ence of these HSV-specific urogenital IgA secreting 
cells may explain, at least in part, the increase in HSV- 
specific IgA titers detected in vaginal secretions after 
HSV-2 challenge. The origin of antigen-specific ASC in 
the genital mucosa is of interest in terms of immuniza- 
tion strategies to elicit protective immunity in the female 
urogenital tract and represents the aim of future studies. 
The results of the present study suggest that HSV- 
specific antibody did not play a major role in clearance 
of virus from the vaginal epithelium during a primary 
genital infection. Virus-specific ASC were not detected 
in the vaginal mucosa after primary vaginal infection 
and HSV-specific antibody was not detected in vaginal 
secretions until 9 days postinfection at which time virus 
had been cleared from the vaginal epithelia. By contrast, 
HSV-specific antibody was present in vaginal secre- 
tions at the time of challenge with wild type virus (data 
not shown) and HSV-specific ASC could be detected in 
the urogenital mucosa after HSV-2 vaginal challenge. 
The specific role of this antibody in protection of the 
urogenital mucosa is unclear. Studies in which HSV- 
immune sera were passivelytransferred after virus inoc- 
ulation have demonstrated a role for antibody in pre- 
venting or limiting the extent of ganglionic infection 
while having little effect on virus replication atthe inocu- 
lation site (Kapoor et al., 1982; KinD et aL, 1982; Sim- 
mons and Nash, 1985). In contrast, other studies have 
shown that systemic administration of a neutralizing 
anti-HSV monoclonal antibody resulted in enhanced 
clearance of virus from the vaginal mucosa (Eis-Hub- 
inger et aL, 1991, 1993). Further, vaginal application of 
HSV antiserum or neutralizing monoclonal antibody has 
been shown to prevent HSV genital infection (Whaley et 
al., 1994). Collectively these studies suggest that local 
antibody is important in protecting the mucosal surface 
and/or local nerve endings from HSV infection regard- 
less of the origin of the antibody. HSV-specific antibody 
in vaginal secretions may therefore provide one barrier 
to infection by direct virus neutralization or prevention 
of virus binding to epithelial cells. If however, this barrier 
is compromised by breaks in the mucosa or a large 
virus inoculum, other mechanisms may be required for 
protection of the genital tract. This model should prove 
useful in understanding the protective function(s) of lo- 
cal humoral and cellular immune responses to a sexu- 
ally transmitted pathogen. 
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